About Vical
Vical is a Healthcare company based in United States founded in 1987. It operates as a therapeutic vaccines for infectious diseases. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its competitors include Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Biological E and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Vical develops therapeutic vaccines for infectious diseases. Its proprietary technology uses plasmid DNA to deliver specific DNA sequences as vaccines, where they are formulated with lipid molecules, or synthetic polymers called poloxamers. Its lead candidate has completed phase III trials for the reduction of cytomegalovirus (CMV) load in patients who have undergone hematopoeitic cell transplant, and phase II trials in patients who have undergone solid organ transplants. Both programs are partnered with Astellas. In addition, the company has additional programs in its pipeline for the treatment of herpes simplex and fungal infections.
- Latest Funding Round$7.8M (USD), Post-IPO
Aug 2016
- InvestorsHHS
& 2 more
Funding Insights of Vical
- Total Rounds 10
- Last Round Post-IPO — $7.8M
- Investors Count 3
All 10 funding rounds of Vical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Vical
Vical has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, AnGes and NIAID.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Gene-based therapies for rare diseases are developed by AnGes. | 1999 | anges.co.jp | Ibaraki, Japan | |
- | – | niaid.nih.gov | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Vical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vical
8 people are tracked at Vical (4 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Vijay B. Samant | President & CEO | Leadership |
Anthony A. Ramos | Chief Financial Officer | Leadership |
Pamela Resch | Sr Exec Director, Regulatory Affairs | Leadership |
Daniel Calderon | Design Department Head | Leadership |
Vinicio Munoz | Jefe de Centro de Diseno Senior Designer | Team |
Marivic Lawrence | Accounting Supervisor | Team |
Adel Reyes | Sr Accountant A/P | Team |
Jean Dantas | DESIGN | Team |
Complete people profiles for Vical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vical
3 dated milestones of Vical across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Vical is founded.
- Funding First funding round.
- Funding Latest funding round, Post-IPO, of $7.8M.
Competitors of Vical
Vical has 9 listed competitors in our database, 8 of them funded. They include Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Biological E, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection | |
| vbivaccines.com | 2001 | Cambridge, United States | $65.07M | 13 | VBI Vaccines is engaged in developing vaccines and immunotherapeutics. | |
| visterrainc.com | 2007 | Cambridge, United States | $116.17M | 79 | Developer of monoclonal antibodies against infectious diseases | |
| clearlabs.com | 2014 | Menlo Park, United States | $171.09M | 55 | Food safety technologies are provided for pathogen identification. |
Detailed competitors of Vical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vical
Websites that share an audience with Vical (vical.com).
Websites whose visitors overlap most with Vical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aicuris.com | 100% | 3.2K | #5,674,145 | View details | |
| verastem.com | 94% | 7.1K | #3,436,777 | View details | |
| bio-quant.com | 90% | – | – | View details | |
| genoptix.com | 90% | – | – | View details | |
| neurocrine.com | 90% | 39.1K | #927,855 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Vical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Vical (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vical
Complete news archive for Vical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vical
Vical was founded in 1987 and raised its 1st funding round 15 years after it was founded.
Vical is headquartered in United States.
Vical develops therapeutic vaccines for infectious diseases. Its proprietary technology uses plasmid DNA to deliver specific DNA sequences as vaccines, where they are formulated with lipid molecules, or synthetic polymers called poloxamers. Its lead candidate has completed phase III trials for the reduction of cytomegalovirus (CMV) load in patients who have undergone hematopoeitic cell transplant, and phase II trials in patients who have undergone solid organ transplants. Both programs are partnered with Astellas. In addition, the company has additional programs in its pipeline for the treatment of herpes simplex and fungal infections.
Vical's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.